Company Overview

Sudeep Pharma Limited (CIN: L24231GJ1989PLC013141) reported strong financial performance for FY26 with consolidated revenue reaching ₹642.26 Crores, representing 28% YoY growth from ₹501.99 Crores in FY25. Profit After Tax grew 26% to ₹174.29 Crores, while EBITDA increased 17% to ₹221.90 Crores with margins at 34.55%.

Strategic Business Developments

The company completed two major corporate actions: (1) An IPO on 28th November 2025 raising ₹9,500 Crores through fresh issue of 1.6 million shares and offer for sale of 13.5 million shares, with net proceeds of ₹8,833.59 Crores; and (2) Acquisition of 85% stake in Nutrition Supplies and Services (Ireland) Limited through subsidiary Sudeep Pharma B.V. for ₹1,285.76 Crores, recognizing goodwill of ₹682.40 Crores and creating NCI liability of ₹297.58 Crores for put option on remaining 15% stake.

Operational Performance

Business segments showed strong growth with Specialty Ingredients revenue up 63% to ₹280 Crores (44% of total revenue) and Pharmaceutical, Food & Nutrition growing 10% to ₹362 Crores. The new Battery Materials vertical under Sudeep Advanced Materials secured 42 active customers with 700 MT initial commercial orders. Manufacturing capacity expanded to 133,000 MT across multiple facilities including the newly commissioned Nandesari greenfield plant (51,200 MT capacity) and Ireland facility (7,500+ MT).

Financial Position

Total equity strengthened to ₹898.09 Crores (vs ₹493.09 Crores in FY25) while total debt stood at ₹148.29 Crores, resulting in net debt of ₹33.60 Crores and net debt-to-equity ratio of 0.04x. Return metrics remained healthy with RoCE at 22.52% and RoE at 19.41%. Working capital cycle extended to 213 days with inventory days increasing to 121 days.

Corporate Governance and Shareholder Matters

The Board proposed a final dividend of ₹1.50 per share, requiring ₹16.94 Crores cash outflow if approved at the 37th AGM scheduled for August 4, 2026 via video conference. Shareholder resolutions include ESOP scheme ratification, director appointments, and remuneration changes. The board comprises 7 directors (3 executive, 4 non-executive independent) with key management including Sujit Bhayani (MD), Shanil Bhayani (Whole Time Director), and Ajay Kandelkar (Whole Time Director).

Forward Outlook

Strategic initiatives position the company for continued growth with battery materials expansion at Dahej (25,000 MT Phase I capacity by Q1 2028), European presence through NSS acquisition, and global warehousing infrastructure in US and Europe. The company maintains 1,120+ customers across 100 countries including 14 Fortune 500 companies and 40+ blue-chip multinationals.